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AbstrAct
Introduction Women in lower income countries 
experience unintended pregnancies at a higher rate 
compared with women in higher income countries. 
Unintended pregnancy is associated with numerous poorer 
health outcomes for both women and their children. In 
Tajikistan, an estimated 26% of married individuals aged 
15–24 years have an unmet need for contraception. 
The strong cultural value placed on childbearing and 
oppositional attitudes towards contraception are major 
barriers to contraceptive uptake in the country. Mobile 
phone ownership is widespread in Tajikistan. The option 
of receiving reproductive health support on your personal 
phone may be an appealing alternative to attending a 
clinic, particularly for young people. The London School of 
Hygiene & Tropical Medicine and the Tajik Family Planning 
Association have partnered to develop and evaluate a 
contraceptive behavioural intervention delivered by mobile 
phone. The intervention was developed in 2015–2016 
guided by behavioural science. It consists of short instant 
messages sent through an app over 4 months, contains 
information about contraception and behaviour change 
methods.
Methods and analysis This randomised controlled trial 
is designed to evaluate the effect of the intervention on 
self-reported acceptability of effective contraception 
at 4 months. 570 men and women aged 16–24 years 
will be allocated with a ratio of 1:1 to receive the 
intervention messages or the control messages about 
trial participation. The messages will be sent through the 
Tajik Family Planning Association’s ‘healthy lifestyles’ app, 
which contains basic information about contraception.
Ethics and dissemination The trial was granted ethical 
approval by the London School of Hygiene & Tropical 
Medicine Interventions Research Ethics Committee on 
16 May 2016 and by the Tajik National Scientific and 
Research Centre on Paediatrics and Child Surgery on 
15 April 2016. The results of the trial will be submitted 
for publication in peer-reviewed academic journals and 
disseminated to study stakeholders.
trial registration number  Clinicaltrial. gov NCT02905513.
Date of registration 14 September 2016.
WHO trial registration dataset http:// apps. who. int/ 
trialsearch/ Trial2. aspx? TrialID= NCT02905513
IntrODuctIOn
Globally in 2012, an estimated 85 million 
pregnancies (approximately 40% of all preg-
nancies) were unintended.1 Women in lower 
income countries experience more unin-
tended pregnancies than in higher income 
countries, with a rate of 54 per 1000 women 
compared with 44 per 1000 women, respec-
tively.1 Unintended pregnancy is associated 
with numerous poorer health and outcomes 
for both women and their children2 including 
decreased psychological well-being3–11 and 
delay in initiating antenatal care.5 11–15 Chil-
dren born of unintended pregnancies are at 
a higher risk of low birth weight and preterm 
birth.16 17 A woman has an unmet need for 
modern contraception if they want to avoid 
a pregnancy but currently use no method or 
a traditional method.18 Fulfilling unmet need 
for contraception is essential in decreasing 
unintended pregnancy; however, in 2014, an 
estimated 225 million women in low-income 
and middle-income countries had an unmet 
need for modern contraception.18
The civil war that followed Tajikistan’s inde-
pendence from the Soviet Union in 1991 
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Protocol
strengths and limitations of this study
 ► The intervention was developed using an established 
approach grounded in behavioural science.
 ► Participants must own a personal Android phone 
to receive the intervention, which means that the 
sample may not represent young people from a 
broad socioeconomic spread.
 ► The randomised trial design will allow us to conclude 
that an observed effect was due to the intervention.
 ► This is the first trial to evaluate an intervention for 
contraception delivered by mobile phone for young 
people in Tajikistan.
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had devastating effects on the Tajik economy and health 
system.19 20 While economic hardship continues, funda-
mental reforms to the healthcare system have instigated 
progressive initiatives, such as the adoption of the Stra-
tegic Plan for Reproductive Health in 2004.21 With regard 
to family planning data, the Tajikistan Demographic and 
Health Survey (DHS) 2012 is the most reliable source at 
present.21 Effective contraception methods are those with 
a less than 10% typical use failure rate at 12 months.22–24 
The effective methods available in Tajikistan are oral 
contraceptive pills, intrauterine devices (IUDs), inject-
ables and implants. While there is some concern about 
the suitability of the progestogen-only injection for adoles-
cents, adolescents are eligible to use the same methods 
as adults; age alone is not a contraindication for use.25 
Despite the availability of the effective methods in Tajiki-
stan, it is estimated that 26% of married individuals aged 
15–24 years have an unmet need for contraception. Total 
unmet need peaks at age 25–29, reflecting the cultural 
norm of early family completion.
The 2012 DHS survey estimated that around 23% of 
all married women and 8% of married individuals aged 
15–24 years report using an effective method, the IUD 
being the most popular.21 Eighty-three per cent of induced 
abortions (all age groups) occur in women not using any 
method.21 The total wanted fertility rate is reported to 
be 3.3 compared with the actual of 3.8, indicating that 
woman have 0.5 children more than desired.21 Opposi-
tional attitudes towards contraception are a barrier to 
use in Tajikistan; 36% of women with an unmet need cite 
their own opposition and 13% cite their partner’s oppo-
sition as the reason for not using contraception.26 Other 
reasons married women with an unmet need gave for not 
using contraception were infrequent/no sex (28%) and 
side effects/health risks/inconvenience (15%).26
Health interventions delivered by mobile phone are 
increasingly popular.27–37 With sensitive topics such as 
reproductive health, the ability to receive information on 
a personal mobile phone may be an appealing alterna-
tive to attend a clinic. While there is some evidence from 
high-income countries that mobile phone-based interven-
tions can increase contraceptive-related behaviours38–40 
and knowledge,41 none of the trials evaluating these 
interventions had a low risk of bias42 according to the 
Cochrane Collaboration’s tool for assessing risk of bias in 
randomised controlled trials.43 The tool assesses risk over 
multiple domains of bias, that is, selection, performance, 
detection, attrition, reporting and other bias. To the best 
of our knowledge, there is only one trial conducted in a 
non-high income country (Cambodia). This trial found 
an effect of postabortion voice messaging with telephone 
counselling support on effective contraceptive use.44
The London School of Hygiene and Tropical Medi-
cine (LSHTM) and the Tajik Family Planning Associa-
tion (TFPA), a member association of the International 
Planned Parenthood Federation (IPPF), are collaborating 
to evaluate an intervention delivered by mobile phone 
for young men and women in Tajikistan to increase the 
acceptability of effective contraception. In Tajikistan in 
2015, there were 98.6 mobile phone subscriptions per 100 
people,45 with 64% owning a smartphone.46 The interven-
tion was developed in 2015–2016 guided by an evidence-
based approach grounded in behavioural science.47 The 
approach involved consultation with the target group to 
identify attitudinal barriers to contraceptive use and an 
iterative process of writing intervention content, testing 
with the target group and refining. This development 
work indicated that short messages delivered by mobile 
phone could be an acceptable way to provide contracep-
tive support to young people.
The aim of this publication is to present the protocol 
for the evaluation of the intervention by randomised 
controlled trial. The trial is designed to evaluate the effect 
of the intervention on young Tajik people’s self-reported 
acceptability of the effective contraception methods avail-
able in Tajikistan. To the best of our knowledge, this will 
be the first trial evaluating an intervention delivered by 
mobile phone designed to increase the acceptability of 
effective contraception in Tajikistan.42
MEtHODs AnD AnAlysIs
Design
This study is a parallel group, individually randomised 
superiority trial with a 1:1 allocation ratio evaluating the 
effect of an intervention delivered by mobile phone appli-
cation (app). Participants randomised to the intervention 
arm will have access to the app and will receive the inter-
vention instant messages. Participants randomised to 
the control arm will have access to the app and receive 
control instant messages about trial participation.
Eligibility criteria
Women and men aged 16–24 years, who own a personal 
Android mobile phone and live in Tajikistan, can provide 
informed consent and can read Tajik or Russian will be 
eligible to take part. Participants must be willing to receive 
messages about contraception on their mobile phone.
recruitment
The trial will be promoted through the distribution of 
flyers through TFPA’s volunteers and youth partner organ-
isation, TFPA’s website and social media sites. Potential 
participants will be provided the link to the enrolment 
pages of the secure online trial database and randomis-
ation system, where they will read the participant infor-
mation sheet (online supplementary file 1) and provide 
informed consent (online supplementary file 2). If they 
do not have adequate internet access, youth organisa-
tion volunteers will provide it. Participants will also have 
the option of completing the paper-based version of the 
consent form.
To maximise the chance of recruiting to target, LSHTM 
conducted a pretrial training in Dushanbe to train local 
staff on all recruitment procedures. The training included 
a discussion about the practicalities of recruitment with a 
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Figure 1 CONSORT diagram.
view to developing the most appropriate strategies (ie, the 
distribution of flyers, an advertisement on TFPA’s website 
and social media sites).
We will report the number of people assessed for eligi-
bility, number of people excluded before randomisation, 
number of participants randomised, number of people 
allocated to the intervention and number of people who 
completed the follow-up and analyse (figure 1).
Intervention
The intervention is informed by the Integrated 
Behavioural Model48 and consists of short mobile phone 
app instant messages that provide contraceptive support 
delivered over 4 months sent through TFPA’s ‘healthy life-
styles’ app. The intervention messages provide informa-
tion about contraception, target beliefs identified in the 
development phase that influence contraceptive use (eg, 
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Figure 2 Logic model of the problem.
misconceptions about the side effects and health risks of 
contraception and belief that non-hormonal methods 
are better because they are not harmful to health) and 
aim to support young women in believing that they can 
influence their reproductive health (see figure 2 for the 
logic model of the problem). The intervention provides 
accurate information about contraception and contains 
the following behaviour change methods,49 adapted for 
delivery by mobile phone: belief selection, facilitation, 
anticipated regret, guided practice, verbal persuasion, 
tailoring, cultural similarity, arguments, shifting perspec-
tive and goal setting. The app itself contains basic infor-
mation about contraception, how to have a ‘healthy 
lifestyle’, youth friendly service point locations and 
contains no behaviour change methods. The app and the 
intervention messages are available in Tajik or Russian, 
according to participants’ preference, which is indicated 
at enrolment.
The messages are tailored according to marital 
status and gender, resulting in four sets of intervention 
messages: (1) female-married, (2) female-not married, 
(3) male-married and (4) male-not married. Most of the 
messages in the four sets overlap, with minor tailoring 
so that the messages are relevant to marital status and 
gender. Marital status is used as a proxy for sexual activity 
because the target group and TFPA considered it inap-
propriate to ask directly about sexual activity. Based on 
the development work with the target group, partici-
pants receive 0–3 messages per day (135 messages for 
female-not married, 155 messages for female-married, 
135 messages for male-not married and 146 messages for 
male-married) for 120 days. Included in the messages 
that intervention recipients receive are seven control 
messages about the importance of their participation and 
reminding them to contact the project coordinator if they 
change their number.
The message sets start with 6–7 days of messages (11 
female-married, 12 female-not married, 12 male-married 
and 13 male-not married) with general information about 
the study, such as what they will receive over the next 120 
days, how to stop the messages, how to choose specific 
times to receive the messages, who to contact if they 
change their number, how to keep the messages private 
and information about who to call if they feel unsafe as a 
result of someone reading the messages (women only). 
On the final 2–3 days, the message sets include four 
messages that indicate that the messages have ended, 
provide a link to the database to complete the follow-up 
questionnaire, reassurance that the information that they 
provide is confidential and a final message stating that 
their participation is helping to determine the best ways 
to provide reproductive health services in Tajikistan.
Details regarding the development of the intervention 
and intervention description will be reported in a forth-
coming publication.
cOntrOl
Participants allocated to the control group will have 
access to the same app pages as the intervention group. 
Control participants will also receive 16 messages about 
trial participation over 120 days. The first 4 days include 
six messages that introduce the study, provide informa-
tion about what they will receive over the next 120 days, 
how to stop the messages and who to contact if they 
change their number. They will then receive two messages 
a month for 3 months—one about the importance of 
their participation and one reminding them to contact 
the project coordinator if they change their number. On 
day 105, they will receive one message about the impor-
tance of their participation. On day 120, participants will 
receive three messages that provide information on how 
to complete the follow-up questionnaire, reassurance that 
the information that they provide is confidential and a 
final message stating that their participation is helping to 
determine the best ways to provide reproductive health 
services in Tajikistan.
All participants will receive usual care (the normal 
care that a young person would receive if they attended 
a service in Tajikistan) and will be free to seek any other 
support, whether existing or new. TFPA’s app is part of 
‘usual care’ for the purpose of the trial and will be ‘new 
usual care’ after the trial.
OutcOMEs
Primary outcome
The primary outcome is the proportion of participants 
reporting that at least one method of effective contra-
ception is acceptable at 4 months postrandomisation. In 
the absence of an existing validated measure of accept-
ability that was appropriate for this context, the primary 
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outcome measure was constructed based on guidelines 
for measuring IBM constructs48 50 51 and tested for face 
validity with the target group. The acceptability of each 
method is measured by the following stems: ‘Using the 
[method] …causes infertility, …causes unwanted side 
effects, …is easy, …is a good way to prevent pregnancy and 
I would recommend the [method] to a friend’. The IUD 
and implant include an additional stem: ‘The [method] 
insertion would not be a problem for me. The response 
options for each scale are: strongly disagree, disagree, 
not sure, agree, strongly agree and I do not know what 
the [method] is. A method is acceptable if participants 
report ‘agree’ or ‘strongly agree’ for all scales except for 
‘…causes infertility’ and ‘…causes unwanted side effects’ 
stems, for which ‘disagree’ or ‘strongly disagree’ denotes 
acceptability (items 1–22 in online supplementary file 3 
and items 4–25 in online supplementary file 4).
secondary outcomes
Secondary outcomes are: the proportion reporting 
current use (or partner’s use) of effective contraception 
(use of effective contraception); the proportion reporting 
that each method of effective contraceptive method is 
acceptable (acceptability of individual methods); the 
proportion reporting use (or partner’s use) of effective 
contraception at any time during the 4 months (discon-
tinuation); the proportion reporting attending a sexual 
health service during the 4 months (service uptake); the 
proportion reporting that they became pregnant and did 
not want a pregnancy during the study (unintended preg-
nancy); and the proportion reporting having (or partner 
having) an abortion during the study (induced abortion).
Process outcomes
The process outcomes are: knowledge of effective contra-
ception; perceived norms in relation to using and commu-
nicating with partners about contraception; personal 
agency in using (women only) and communicating with 
partners about contraception; and intention to use effec-
tive contraception (women only) and intervention dose 
received.
DAtA cOllEctIOn
Data will be collected at baseline and at 4 months postran-
domisation using questionnaires, which we tested for face 
validity with 27 people from the target group. We asked 
people to comment on the length of the questionnaires, 
the comprehensibility of the questions, the meaning of 
the scales and suggestions for improvement. All data will 
be entered onto the trial database system, which is on 
LSHTM’s secure server. At both time points, participants 
can either fill out a paper-based version of the question-
naire at the recruitment site, provide the data over the 
phone with research staff or enter data directly onto the 
online system, according to their preference. If partici-
pants provide their questionnaire data by paper or over 
the telephone, research staff will enter these data onto 
the system.
baseline data collected
At baseline we will measure the primary outcome and 
collect the following personal and demographic data: 
full name, mobile phone number, email address, date 
of birth, gender, marital status, number of children, 
ethnicity, occupation, education level, current pregnancy 
intention, current method and how they found out about 
the study (online supplementary file 3).
Follow-up data collected
At 4 months, we will measure the primary, secondary 
and process outcomes and collect the following data: 
if participants report using an effective method, where 
they obtained it, current pregnancy intention, whether 
they knew someone else that took part in the study and, 
if so, if they read each other’s messages (contamination), 
if they have experienced physical violence since being 
in the study and if anything good or bad happened as 
a result of receiving the messages (online supplemen-
tary file 4).
If participants do not complete the questionnaire them-
selves, local research staff will contact them to collect their 
data. For participants that report use of effective contra-
ception at follow-up, local research staff will attempt to 
locate the service records to objectively verify use.
Methods to maximise follow-up response
The pretrial training also included training in follow-up 
procedures. It emphasised the importance of ensuring 
that participants understand that participation involves 
completing a 4-month questionnaire and to poten-
tially receiving daily messages about contraception for 
4 months. The control messages, also sent to participants 
allocated to the intervention, are an effort to keep partic-
ipants engaged. Staff will contact non-responders up to 
three times for their follow-up data. Follow-up will end 
6 months after the last participant has been randomised 
or after staff has attempted to contact all non-responders 
three times, whichever comes first.
See figure 3 for the schedule of enrolment, interven-
tions and assessments.
Allocation and protecting against bias
Randomisation will occur immediately after baseline 
data is submitted on the trial database and randomis-
ation system. The allocation sequence is generated by 
the remote computer-based randomisation software, 
ensuring that investigators are unaware of allocation 
before it occurs. Due to the nature of the intervention, 
participants will be aware of the allocation soon after 
they start receiving the messages. Local research staff 
collecting outcome data will not be made aware of allo-
cation unless this is revealed to them by the participant. 
Researchers that analyse the data will be masked to treat-
ment allocation.
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Figure 3 Schedule of enrolment, interventions and assessments.
Intervention delivery
After participant baseline data has been entered, a confir-
mation of enrolment screen will provide instructions 
on how to install the app. When participants install the 
app, they will be prompted to enter the mobile phone 
number they entered on the baseline questionnaire. The 
trial database and randomisation system will then send 
the local app platform the following information: gender, 
marital status, language preference, allocation and date 
of enrolment. Participants will then have access to the 
app and will receive either the control or intervention 
messages, according to their allocation. Within the app, 
participants can choose when they want to receive the 
messages and they can also stop the messages. If partici-
pants install the app after 13:00, they will receive the first 
message the following day.
sample size
The trial is powered to detect a 15% increase in accept-
ability of effective contraception in the intervention group 
compared with the control group. Other studies have 
found smaller increases in behaviour with similar inter-
ventions, for example, Castaño et al.39 Because attitudinal 
change is likely to be easier to achieve than behavioural 
change, we decided to power the trial to detect a larger 
difference. Four hundred and fifty-four participants will 
allow for 90% power to detect a 15% absolute increase in 
acceptability, assuming 50% acceptability in the control 
group (ie, 50% in the control vs 65% in the intervention, 
an OR of 1.86). Fifty per cent baseline acceptability is 
used in the absence of published data on acceptability in 
this context. If the actual baseline acceptability is higher 
or lower than 50%, the trial is still sufficiently powered 
to detect an absolute difference of 15%. For example, 
if the proportion in the control arm is 75%, there will 
be 90% power to detect an absolute difference of 12% 
(corresponding to 87% acceptability in the interven-
tion group and an OR of 2.23). Allowing for 20% loss to 
follow-up, 570 people will be randomised.
DAtA MAnAgEMEnt
We did not convene a Data Monitoring and Ethics 
Committee as the intervention provides support and is 
unlikely to produce adverse effects. We have convened a 
Trial Steering Committee, and they have agreed to take 
on the monitoring of ethical aspects of the trial. The trial 
sponsor may audit the trial according to their own risk 
assessment and schedule.
Personal details entered onto the trial database and 
randomisation system will be stored on LSHTM’s secure 
server. Personally identifiable information exported from 
the database will be stored separately from anonymised 
research data. Participants’ mobile phone numbers, 
but no other personal details, will be stored in the local 
platform that sends the messages through the app. Any 
signed paper consent forms and questionnaires will be 
kept in a data enclave at TFPA. All data arising from the 
study will be kept confidential and only accessible to 
researchers directly involved in it. Personally identifiable 
data will not be kept longer than necessary and will be 
deleted within 3 months following study completion. We 
will retain primary research data for 10 years following 
study completion.
AnAlysEs
general statistical considerations
The analysis of the data will follow the plan specified below. 
There will be no interim analyses and therefore no stop-
ping rules. All analyses will be according to randomised 
arm, and only participants with complete outcome data 
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will be included in the primary analysis (a complete case 
analysis). All statistical tests will be two sided. All effect 
estimates will be reported with a 95% CI and associated 
p value. Statistical significance will be considered at the 
5% level. Analyses will be conducted using Stata 15.
loss to follow-up
To investigate whether loss to follow-up differs by arm, 
we will report this descriptively and use a χ2 test. We will 
use logistic regression to compare baseline characteristics 
of participants that completed 4-month follow-up against 
participants that did not. We will report predictors of loss 
to follow-up and investigate whether the effect of these 
differs by arm by testing for an interaction.
Assumptions about missing data
As we are not aware of similar trials, it is not possible to 
investigate the pattern of missing data. The complete case 
analysis assumes that missing data for participants that did 
not complete follow-up are similar to data from partici-
pants that completed follow-up, conditionally based on 
baseline covariates included in the analysis model (ie, that 
data is missing at random).52 If participants that complete 
follow-up are more likely to find an effective method 
acceptable compared with those that are lost to follow-up, 
the observed proportion may overestimate acceptability.52
Missing covariates
The database requires all items on the baseline question-
naire to be submitted to randomise. Therefore, there will 
be no missing baseline covariates.
Primary analysis
Descriptive analysis
We will report a flow diagram of trial participation, as 
recommended in the CONSORT guidelines.53 We will 
report the baseline characteristics by treatment arm. 
We will also explore the baseline factors associated with 
retention (see above).
Analysis of the primary outcome
The primary outcome is binary, and we will compare the 
crude proportion reporting at least one method is accept-
able in each group. We will estimate the difference between 
the groups using logistic regression and will report the OR 
along with the 95% CI and p value for evidence against 
the absence of intervention effect from the model. The 
primary analysis regression will be adjusted for baseline 
covariates likely to be associated with the outcome in 
order to improve the efficiency of the analysis and avoid 
chance imbalances.54 These prespecified covariates that 
we will adjust for are: use (using effective contraception/
not using effective contraception); pregnancy intention 
(wants to avoid/other); gender (female/male), age 
(16–19/20–24 years); number of children (0/1+); highest 
education level completed (university/other) and accept-
ability of effective contraception at baseline (at least one 
method acceptable/no methods acceptable). We will also 
report the crude OR between arms.
Analysis of the secondary outcomes
The analysis of the secondary outcomes will be the similar 
to the analysis of the primary outcome. We will estimate 
the difference between the groups using logistic regres-
sion, report ORs with 95% CIs and p values. All regres-
sions will be adjusted for the prespecified covariates as 
above (although with the acceptability of individual 
methods, the outcome at baseline will replace accept-
ability of effective contraception).
Analysis of the process outcomes
The process outcomes perceived norms, personal agency 
and intention are comprised of ordinal scales. Each scale 
will be analysed individually using ordered logistic regres-
sion to estimate proportional ORs. For knowledge, each 
correct answer will receive one point. The points will 
be summed, and an overall score will be produced. We 
will use linear regression to test for a difference in mean 
scores between the arms.
To assess the ‘dose’ of the intervention that the inter-
vention participants received, we will analyse the number 
of messages that participants reported to have read (all, 
most, some and none) and whether they stopped the 
messages. This will be reported descriptively.
Additional analyses
Sensitivity analyses
We will conduct sensitivity analyses regarding the missing 
data. In the first sensitivity analysis, we will consider that 
data are not missing at random and that participants lost 
to follow-up did not find at least one method accept-
able. In the second, we will adjust for the main baseline 
predictors of missingness. Both sensitivity analyses will be 
adjusted for the pre-specified covariates as above.
Subgroup analysis
Recognising that the trial is not powered to detect effect 
differences in subgroups, we will conduct exploratory 
subgroup analyses for the primary outcome to determine 
if the intervention effect varies by baseline characteristics. 
The prespecified subgroups are: gender (female/male); 
age (split at the median); marital status (married/not 
married); number of children (0/1+); ethnicity (Tajik/
other); occupation (in education/other); highest educa-
tion level completed (university/other) and pregnancy 
intention (wants to avoid/other). Within the prespecified 
subgroups, we will assess heterogeneity of treatment effect 
with a test for interaction.55–59 Interaction test p values will 
be presented but will be interpreted with caution, due to 
the exploratory nature, the multiple tests performed and 
the low power of the interaction test. We will estimate ORs 
along with 95% CIs for each subgroup without p values. 
As this is an exploratory analysis of potentially influential 
characteristics that are not justified a priori, we will not 
hypothesise effect directions.
Contamination
To assess the potential for contamination, we will report 
the proportion of control group participants that read 
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another participant’s messages and the proportion of 
intervention participants whose messages were read by 
another participant.
Participants’ rights and safety
Participants will have the right to withdraw at any time 
during their involvement, without having to give a reason. 
Participants can withdraw by contacting the project coor-
dinator. Acting on participants’ requests to withdraw 
from the trial, participants’ status will be changed to 
‘withdrawn’, and the person will be excluded from the 
list of participants that are due to follow-up. Participants’ 
participation and personal identifiable data will remain 
confidential and research data will be anonymised.
In the development phase, we explored young people’s 
views on confidentiality about receiving messages on 
their mobile phone. While the large majority of partic-
ipants reported that they were not concerned about 
receiving messages about contraception on their phone, 
it is possible that some participants will want to keep 
the messages confidential from certain people (eg, 
partner and parents) and that these people might view 
the messages. The messages remind participants that they 
can delete the messages and provide instructions on how 
to keep the messages private. Towards the beginning of 
the intervention, a message provides female participants 
with information on support services that they can contact 
if they feel unsafe as a consequence of the messages being 
read. (This information will not be provided for male 
participants as TFPA advised that male participants not 
feeling safe as a consequence of the messages being read 
is not culturally realistic.) We will review physical violence 
during participants’ involvement in the trial reported on 
the follow-up questionnaire.
DIscussIOn
The results of this trial will provide evidence for the effect 
of the intervention on young Tajik women and men’s atti-
tudes towards effective contraception. The analysis of the 
secondary and process outcomes may provide evidence 
for the effect of the intervention on use of effective 
contraception, attitudes towards the individual effective 
methods, service use, unintended pregnancy, induced 
abortion and on the psychological processes that may 
have been altered by the intervention.
As the intervention will be delivered through TFPA’s 
Android app, participants are required to own a personal 
Android mobile phone. While the formative work indi-
cated that the majority of young people in Tajikistan did 
own a personal Android mobile phone, those who do not 
own a smartphone may be those who are less likely to find 
at least one method of effective contraception acceptable. 
However, considering the rapid increase in smartphone 
ownership, it is reasonable to assume that ownership will 
be an option for a greater proportion of young people 
across different socioeconomic communities in the 
coming years.
The trial is assessing the effect of sending instant 
messages containing behaviour change methods in addi-
tion to the app; it is not assessing the effect of the app 
itself. It is possible that the app, which provides basic 
information about contraception, could increase the 
acceptability of effective contraception. If the app itself is 
very effective, the added benefit of the instant messages 
will be lower.
If the trial demonstrates that the intervention increases 
the acceptability of effective contraception in Tajikistan, 
the results could inform the design of a trial to evaluate 
the effect of the intervention on unintended pregnancy.
PrOtOcOl AMEnDMEnts
Any important changes to the protocol will be submitted 
to the LSHTM Interventions Research Ethics Committee 
as an amendment. Trial documentation will be updated 
accordingly and will be implemented once the Committee 
has approved the changes. OLM will communicate any 
changes relevant to local staff.
DIssEMInAtIOn
The research results will be cowritten by LSHTM and TFPA 
and submitted for publication in peer-reviewed academic 
journals. We will adhere to the International Committee 
of Medical Journal Editors authorship criteria. We will 
disseminate findings to all the study stakeholders. 
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